Loading the company…
Loading the company…
Families: Peripheral nerve stimulation & intrathecal pumps.
All companies · Product and company coverage
In the last ten years FDA made 1 decision for Curonix (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 1 procedure family, the most in 2024 (1). The latest was on 2024-06-20.
| Family | Decisions on record |
|---|---|
| Peripheral nerve stimulation & intrathecal pumps | 1 |
| Date | Kind | Number | Device |
|---|---|---|---|
| 2024-06-20 | 510(k) | K233162 | Freedom Peripheral Nerve Stimulator (PNS) System |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Curonix.
In 2025, Curonix reported engagement with 2,802 surgeons and other clinicians in the states MedaRep covers, worth $813K in consulting, speaking, meals and travel for its device products, the most in Texas ($127K to 229). Royalties are left out.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: Texas ($127K, 229 engaged), Wisconsin ($99K, 25 engaged), California ($88K, 338 engaged), Ohio ($81K, 106 engaged), Florida ($58K, 472 engaged).